3,3-dimethyl-nonanoic acid | 22167-93-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3,3-dimethyl-nonanoic acid
• 英文别名: 3,3-Dimethyl-nonansaeure；3,3-dimethylnonanoic acid
• CAS: 22167-93-7
• 化学式: C₁₁H₂₂O₂
• 分子量: 186.294
• InChiKey: YTISNWDNLZEHQA-UHFFFAOYSA-N

物化性质

• 沸点：
  142-148 °C(Press: 13 Torr)
• 密度：
  0.9038 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  13
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,3-dimethyl-nonanoic acid 在 氯化亚砜 、 乙醚 、 硫酸 作用下， 生成 4,4-dimethyl-decanoic acid
  参考文献：
  名称：

  Lukes; Hofman, Collection of Czechoslovak Chemical Communications, 1958, vol. 23, p. 1110,1118

  摘要：

  DOI：
• 作为产物：
  描述：

  5-methoxy-3,3-dimethyl-5-oxopentanoic acid 在 甲醇 、 氢氧化钾 、 sodium 作用下， 生成 3,3-dimethyl-nonanoic acid
  参考文献：
  名称：

  Kimura; Tanaka, Chemical and pharmaceutical bulletin, 1958, vol. 6, p. 9,10

  摘要：

  DOI：

文献信息

• Pd-Catalyzed Dual-γ-1,1-C(sp³)–H Activation of Free Aliphatic Acids with Allyl–O Moieties
  作者：Jayabrata Das、Tanay Pal、Wajid Ali、Sumeet Ranjan Sahoo、Debabrata Maiti

  DOI：10.1021/acscatal.2c02790

  日期：2022.9.16

  long-chain ones have been used as substrates in the protocol. A mechanistic investigation has been carried out and suggests C–H activation to be the rate-determining step and a subsequent allylic C–H activation in the reaction. The synthesized lactones having α,β-unsaturated fragments attached are expected to be useful in the synthesis of complex molecules via further synthetic manipulation.

  烯丙醇代表了 C-H 官能化反应中一类独特的偶联伙伴。在这项工作中，我们报告了一个简单的策略，涉及双 1,1-C(sp 3)–H 活化游离脂肪酸，导致直接合成在 γ 位含有 α,β-不饱和基团的 γ-内酯。各种烯丙醇，包括伯醇、仲醇、叔醇等，已被用作合适的偶联配偶体，以产生各种 γ-内酯。包括长链脂肪酸在内的许多脂肪酸已被用作协议中的底物。已经进行了机理研究，并表明 C-H 活化是反应中的速率决定步骤和随后的烯丙基 C-H 活化。所合成的具有 α,β-不饱和片段的内酯有望通过进一步的合成操作用于合成复杂分子。
• As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
  申请人：——

  公开号：US20020013304A1

  公开（公告）日：2002-01-31

  A method is provided for enhancing a female individual's sexual desire and responsiveness. The method involves administration of a pharmaceutical formulation containing an effective amount of an androgenic agent, wherein administration is on an as-needed basis rather than involving chronic pharmacotherapy. Local delivery may be accomplished via administration to the vagina, vulvar area or urethra of the individual, although oral administration is preferred for those androgenic agents that are orally active. Formulations and kits for carrying out the method are provided as well.

  提供了一种提高女性性欲和性反应能力的方法。该方法包括给药含有有效量雄性激素的药物制剂，其中给药是按需给药，而不是长期药物治疗。局部给药可通过给药到个人的阴道、外阴部或尿道来实现，但对于那些口服活性的雄性激素制剂来说，口服给药是首选。此外，还提供了用于实施该方法的制剂和试剂盒。
• As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
  申请人：——

  公开号：US20030022875A1

  公开（公告）日：2003-01-30

  A method is provided for enhancing a female individual's sexual desire and responsiveness. The method involves oral administration of a dosage form containing an effective amount of an orally active androgenic agent, and is on an as-needed basis rather than involving chronic pharmacotherapy. Oral pharmaceutical compositions, dosage forms and kits for carrying out the method are provided as well.

  提供了一种提高女性性欲和性反应能力的方法。该方法包括口服含有有效量口服活性雄性激素的剂型，并且是按需给药，而不是长期药物治疗。此外，还提供了用于实施该方法的口服药物组合物、剂型和试剂盒。
• Treatment of dyspareunia with topically administered nitroglycerin formulations
  申请人：——

  公开号：US20040044080A1

  公开（公告）日：2004-03-04

  Methods and formulations for treating dyspareunia are provided. A pharmaceutical composition formulated so as to contain a therapeutically effective amount of nitroglycerin is administered to the vagina or vulvar area of the individual undergoing treatment. Preferred formulations are immediate release formulations in which at least 80% of the nitroglycerin in the formulation is released therefrom within 4 hours following administration. The formulations may contain one or more additional active agents, e.g., agents that are also useful to treat dyspareunia and/or potentiate the action of nitroglycerin. Such additional agents include vasoactive agents such as prostaglandins, phosphodiesterase inhibitors, androgens such as testosterone, estrogens such as estradiol, and selective modulators of estrogen and androgen receptors. A kit for a patient to use in the self-administration of the formulation is also provided.

  本研究提供了治疗性交困难的方法和制剂。将配制成含有治疗有效量硝化甘油的药物组合物施用到接受治疗者的阴道或外阴部位。首选的制剂是速释制剂，其中制剂中至少 80% 的硝酸甘油在给药后 4 小时内从制剂中释放出来。制剂可含有一种或多种额外的活性剂，例如，也可用于治疗性交困难和/或增强硝酸甘油作用的制剂。此类附加制剂包括血管活性剂，如前列腺素、磷酸二酯酶抑制剂、雄激素，如睾酮、雌激素，如雌二醇，以及雌激素和雄激素受体的选择性调节剂。此外，还提供了一种供患者用于自行服用制剂的试剂盒。
• As-needed administration of an androgenic agent to enhance female desire and responsiveness
  申请人：Wilson F. Leland

  公开号：US20050070516A1

  公开（公告）日：2005-03-31

  A method is provided for enhancing a female individual's sexual desire and responsiveness. The method involves administration of a pharmaceutical formulation containing an effective amount of an androgenic agent, wherein administration is on an as-needed basis rather than involving chronic pharmacotherapy. Local delivery may be accomplished via administration to the vagina, vulvar area or urethra of the individual, although oral administration is preferred for those androgenic agents that are orally active. Formulations and kits for carrying out the method are provided as well.

  提供了一种提高女性性欲和性反应能力的方法。该方法包括给药含有有效量雄性激素的药物制剂，其中给药是按需给药，而不是长期药物治疗。局部给药可通过给药到个人的阴道、外阴部或尿道来实现，但对于那些口服活性的雄性激素制剂来说，口服给药是首选。此外，还提供了用于实施该方法的制剂和试剂盒。